Header Logo

Connection

VIVEK SUBBIAH to Mutation

Back to Details
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Mutation.
VIVEK SUBBIAH
Connection Strength
3.097
Mutation
  1. Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers. Mol Cancer Ther. 2021 10; 20(10):1769-1776.
    View in: PubMed
    Score: 0.200
  2. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 08; 9(8):491-501.
    View in: PubMed
    Score: 0.196
  3. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 07; 8(7):836-849.
    View in: PubMed
    Score: 0.158
  4. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018 01 01; 36(1):7-13.
    View in: PubMed
    Score: 0.153
  5. Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. J Natl Cancer Inst. 2017 10 01; 109(10).
    View in: PubMed
    Score: 0.152
  6. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267.
    View in: PubMed
    Score: 0.149
  7. Towards precision oncology in RET-aberrant cancers. Cell Cycle. 2017 05 03; 16(9):813-814.
    View in: PubMed
    Score: 0.147
  8. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer. 2024 03 26; 23(1):64.
    View in: PubMed
    Score: 0.060
  9. Targeting All BRAF Alterations: The (Re)-Search Continues. JCO Precis Oncol. 2024 Feb; 8:e2300670.
    View in: PubMed
    Score: 0.059
  10. Impact of tissue-agnostic approvals on management of primary brain tumors. Trends Cancer. 2024 Mar; 10(3):256-274.
    View in: PubMed
    Score: 0.059
  11. The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications. Clin Cancer Res. 2023 11 14; 29(22):4669-4678.
    View in: PubMed
    Score: 0.058
  12. Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer. 2024 01; 130(2):186-200.
    View in: PubMed
    Score: 0.058
  13. RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer Discov. 2023 09 06; 13(9):2012-2031.
    View in: PubMed
    Score: 0.057
  14. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. Clin Cancer Res. 2023 08 01; 29(15):2753-2760.
    View in: PubMed
    Score: 0.057
  15. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023 05; 29(5):1103-1112.
    View in: PubMed
    Score: 0.056
  16. Top advances of the year: Precision oncology. Cancer. 2023 06 01; 129(11):1634-1642.
    View in: PubMed
    Score: 0.056
  17. Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood. 2023 03 02; 141(9):996-1006.
    View in: PubMed
    Score: 0.055
  18. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. Mol Cancer Ther. 2022 06 01; 21(6):871-878.
    View in: PubMed
    Score: 0.053
  19. Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation. JCO Precis Oncol. 2022 04; 6:e2100371.
    View in: PubMed
    Score: 0.052
  20. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022 01; 23(1):53-64.
    View in: PubMed
    Score: 0.051
  21. The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. BMC Med. 2021 09 15; 19(1):209.
    View in: PubMed
    Score: 0.050
  22. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021 02; 32(2):261-268.
    View in: PubMed
    Score: 0.047
  23. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 08 27; 383(9):813-824.
    View in: PubMed
    Score: 0.047
  24. Dual inhibition of BRAF and mTOR in BRAFV600E -mutant pediatric, adolescent, and young adult brain tumors. Cold Spring Harb Mol Case Stud. 2020 08; 6(4).
    View in: PubMed
    Score: 0.047
  25. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 09; 21(9):1234-1243.
    View in: PubMed
    Score: 0.046
  26. Progresses Toward Precision Medicine in RET-altered Solid Tumors. Clin Cancer Res. 2020 12 01; 26(23):6102-6111.
    View in: PubMed
    Score: 0.046
  27. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
    View in: PubMed
    Score: 0.046
  28. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080.
    View in: PubMed
    Score: 0.045
  29. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
    View in: PubMed
    Score: 0.044
  30. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clin Cancer Res. 2019 10 01; 25(19):5832-5842.
    View in: PubMed
    Score: 0.043
  31. Personalizing Precision Oncology: From Light Microscope to Molecular Microscope. J Natl Compr Canc Netw. 2019 07 01; 17(7):886-888.
    View in: PubMed
    Score: 0.043
  32. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601.
    View in: PubMed
    Score: 0.039
  33. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. Curr Oncol Rep. 2017 Oct 13; 19(12):78.
    View in: PubMed
    Score: 0.038
  34. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
    View in: PubMed
    Score: 0.037
  35. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 10; 15(10):2475-2485.
    View in: PubMed
    Score: 0.035
  36. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology. 2016; 90(6):339-46.
    View in: PubMed
    Score: 0.035
  37. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
    View in: PubMed
    Score: 0.033
  38. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015 Aug 20; 373(8):726-36.
    View in: PubMed
    Score: 0.033
  39. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9.
    View in: PubMed
    Score: 0.032
  40. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018.
    View in: PubMed
    Score: 0.032
  41. Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS One. 2014; 9(8):e93676.
    View in: PubMed
    Score: 0.031
  42. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer. 2014 Dec; 14(6):468-74.
    View in: PubMed
    Score: 0.030
  43. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One. 2014; 9(2):e89388.
    View in: PubMed
    Score: 0.030
  44. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes. Clin Cancer Res. 2023 12 01; 29(23):4844-4852.
    View in: PubMed
    Score: 0.015
  45. Variant allele frequency: a decision-making tool in precision oncology? Trends Cancer. 2023 12; 9(12):1058-1068.
    View in: PubMed
    Score: 0.014
  46. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118.
    View in: PubMed
    Score: 0.014
  47. The emerging role of PI3K inhibitors for solid tumour treatment and beyond. Br J Cancer. 2023 06; 128(12):2150-2162.
    View in: PubMed
    Score: 0.014
  48. Drugging KRAS: current perspectives and state-of-art review. J Hematol Oncol. 2022 10 25; 15(1):152.
    View in: PubMed
    Score: 0.014
  49. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep. 2022 05 24; 12(1):8701.
    View in: PubMed
    Score: 0.013
  50. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.012
  51. Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat Rev. 2021 05; 96:102179.
    View in: PubMed
    Score: 0.012
  52. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835.
    View in: PubMed
    Score: 0.012
  53. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends Cancer. 2021 01; 7(1):15-28.
    View in: PubMed
    Score: 0.012
  54. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 08 27; 383(9):825-835.
    View in: PubMed
    Score: 0.012
  55. RET Solvent Front Mutations Mediate Acquired?Resistance to Selective RET Inhibition in?RET-Driven Malignancies. J Thorac Oncol. 2020 04; 15(4):541-549.
    View in: PubMed
    Score: 0.011
  56. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 09 15; 25(18):5475-5484.
    View in: PubMed
    Score: 0.011
  57. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
    View in: PubMed
    Score: 0.010
  58. BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study. J Clin Oncol. 2018 12 10; 36(35):3477-3484.
    View in: PubMed
    Score: 0.010
  59. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188.
    View in: PubMed
    Score: 0.010
  60. Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. J Natl Compr Canc Netw. 2017 07; 15(7):863-866.
    View in: PubMed
    Score: 0.009
  61. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.
    View in: PubMed
    Score: 0.009
  62. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017 Jul 15; 23(14):3657-3666.
    View in: PubMed
    Score: 0.009
  63. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365.
    View in: PubMed
    Score: 0.009
  64. Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Mol Cancer Ther. 2016 04; 15(4):533-47.
    View in: PubMed
    Score: 0.009
  65. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. 2016 Mar 01; 122(5):702-11.
    View in: PubMed
    Score: 0.008
  66. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62.
    View in: PubMed
    Score: 0.008
  67. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94.
    View in: PubMed
    Score: 0.008
  68. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
    View in: PubMed
    Score: 0.008
  69. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med. 2014 Dec; 18(101):331-9.
    View in: PubMed
    Score: 0.008
  70. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 01; 20(23):5956-63.
    View in: PubMed
    Score: 0.008
  71. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26.
    View in: PubMed
    Score: 0.008
  72. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.